Resmed Inc (RMD)
NYSE:RMD
Want to see RMD full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
2.89Last Year’s EPS
2.55Same Quarter Last Year
Moderate Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a broadly positive operational and financial picture: durable revenue growth (11% headline, 8% constant), material gross margin expansion (+290 bps YoY), double‑digit EPS growth (~21%), strong free cash flow and capital returns, successful product rollouts (fabric masks, AirSense 11) and large real‑world evidence supporting a GLP‑1 demand tailwind. Management acknowledged and is actively managing a set of medium‑term headwinds — including rising SG&A and R&D investments, isolated investment write‑downs, RCS vertical challenges, component cost pressures, and near‑term acquisition dilution — but positioned these as manageable given a strong balance sheet, ongoing supply chain productivity initiatives, and targeted M&A.Company Guidance
Revenue Growth
Group revenue of $1.43 billion, up 11% on a headline basis and 8% on a constant currency basis versus prior year.
Gross Margin Expansion
Gross margin improved to 62.8%, +290 basis points year‑over‑year and +50 basis points sequentially; company reiterates FY26 gross margin guidance of ~62%–63% and a multi‑year plan for continued accretion through 2030.
Earnings and Operating Profit
Non‑GAAP diluted EPS grew ~21%; operating profit rose 18% year‑over‑year and operating margin expanded to 36.7% from 34.4%.
Strong Free Cash Flow and Balance Sheet
Free cash flow of $520 million (quarter called out by management) and cash flow from operations of $554 million; ended quarter with $1.7 billion cash, $664 million gross debt and ~$996 million net cash; >100% free cash flow conversion and $262 million returned to shareholders in the quarter (including $175 million share repurchase and a $0.60 quarterly dividend).
Product Adoption — Masks and Devices
Global masks & other sales increased 12% (devices +6% on a constant currency basis); Americas masks +14% (even excluding VertuOx contribution Americas masks still grew double digits). Fabric mask rollouts (AirTouch N30i, F30i Comfort, F30i Clear) showing strong early adoption and positive feedback.
Clinical / Real‑World Evidence & GLP‑1 Synergy
Large real‑world analyses: cohort of 1.7M patients shows PAP patients who later start GLP‑1 have +5.1% (2‑yr) and +6.2% (3‑yr) resupply rates; claims cohort of 2.1M shows patients with scripts for both PAP and GLP‑1 are 11% more likely to start PAP and >3% more likely to have a resupply at 1 year and >6% at 3 years — highlighting a material demand‑generation tailwind.
Strategic M&A and Product Expansion
Signed agreement to acquire Noctrix Health for $340 million (expected close ~June 1, 2026); Noctrix run‑rate revenue ~ $24 million with higher growth and higher gross margins than ResMed; tuck‑in expected to expand sleep health portfolio (RLS) and leverage ResMed distribution and reimbursement capabilities.
Operational / Supply Chain Progress
Reported continued supply chain optimization (more sea vs air freight, component/vendor management, manufacturing & logistics efficiency) contributing to gross margin improvement and management guidance that a pipeline of initiatives will support future margin accretion.
RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 30, 2026 | $213.18 | $204.41 | -4.11% |
Jan 29, 2026 | $256.25 | $256.95 | +0.27% |
Oct 30, 2025 | $250.34 | $245.00 | -2.13% |
Jul 31, 2025 | $269.30 | $276.49 | +2.67% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Resmed Inc (RMD) report earnings?
Resmed Inc (RMD) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Resmed Inc (RMD) earnings time?
Resmed Inc (RMD) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RMD EPS forecast?
RMD EPS forecast for the fiscal quarter 2026 (Q4) is 2.89.